Global Leading Market Research Publisher QYResearch announces the release of its latest report “Nuclear Medicine – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. For healthcare systems, oncology specialists, and medical imaging investors, the convergence of diagnostic precision and targeted therapy embodied in nuclear medicine represents one of the most powerful tools in modern medicine. Traditional diagnostic imaging provides anatomical information, but often fails to reveal the molecular and functional characteristics that distinguish malignant from benign disease or guide treatment selection. Nuclear medicine addresses this gap through the use of radiopharmaceuticals—radioactive compounds that target specific organs, tissues, or cellular receptors—enabling both highly sensitive molecular imaging and targeted radionuclide therapy. This report delivers a comprehensive strategic assessment of a market poised for strong growth, quantifying the value proposition that is driving adoption across oncology, cardiology, and neurology as theranostic approaches—combining diagnostic and therapeutic capabilities in a single platform—transform patient care.
Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Nuclear Medicine market, including market size, share, demand, industry development status, and forecasts for the next few years. The global market for Nuclear Medicine was estimated to be worth US$ 6875 million in 2024 and is forecast to a readjusted size of US$ 11090 million by 2031 with a CAGR of 7.4% during the forecast period 2025-2031. Nuclear Medicine, or Radiopharmaceuticals, are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
Market Drivers
The nuclear medicine market is experiencing significant growth due to the increasing prevalence of chronic diseases, including cancer, cardiovascular diseases, and neurological disorders, which require advanced diagnostic and therapeutic solutions. Nuclear medicine provides highly targeted treatment, such as radioisotope therapy, and is crucial for precise imaging techniques like PET and SPECT, which offer better disease detection and management. Advances in radiopharmaceuticals, such as the development of new radioisotopes, and the rising demand for personalized medicine further fuel the market’s expansion. Additionally, the growing emphasis on early diagnosis and treatment monitoring in healthcare systems, along with the availability of funding for research and development in nuclear medicine, contributes to market growth.
Market Challenges
Despite its advantages, the nuclear medicine market faces challenges related to the high costs of nuclear medicine treatments and imaging technologies. The infrastructure required for nuclear medicine, including specialized facilities, trained professionals, and the availability of radiopharmaceuticals, can be prohibitively expensive, especially in developing regions. Additionally, concerns over the safe handling and disposal of radioactive materials, regulatory hurdles, and the relatively short half-life of certain isotopes create logistical difficulties in terms of production, distribution, and patient access. These challenges can limit the widespread adoption of nuclear medicine, particularly in low-resource healthcare settings.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/3678398/nuclear-medicine
Market Trajectory: Accelerating Growth Driven by Theranostics and Oncology Applications
The projected 7.4% CAGR reflects a market benefiting from the emergence of theranostic approaches—where diagnostic imaging identifies patients likely to benefit from targeted radionuclide therapy—and the expanding oncology application landscape. According to recent data from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and industry analysts, the number of FDA-approved theranostic pairs has increased from fewer than five in 2015 to over fifteen in 2024, with the most prominent example being the PSMA-targeted approach for prostate cancer: Ga-68 PSMA-11 for diagnostic PET imaging and Lu-177 PSMA-617 for therapy.
Several factors are driving market expansion. The rising global incidence of cancer—projected to reach 28 million new cases annually by 2040—has created demand for both diagnostic and therapeutic nuclear medicine applications. The success of radioligand therapy in prostate cancer and neuroendocrine tumors has validated the theranostic concept and spurred development of similar approaches across multiple tumor types. Additionally, advances in cyclotron and generator technology have improved the availability of key isotopes, including technetium-99m, fluorine-18, and lutetium-177.
Product Segmentation: Diagnostic Nuclear Medicine and Therapeutic Nuclear Medicine
The market’s segmentation by product type—Diagnostic Nuclear Medicine and Therapeutic Nuclear Medicine—reveals the dual role of nuclear medicine in patient care.
Diagnostic Nuclear Medicine encompasses radiopharmaceuticals used with PET (positron emission tomography) and SPECT (single photon emission computed tomography) imaging to detect and characterize disease. Fluorodeoxyglucose (FDG), labeled with fluorine-18, remains the most widely used diagnostic radiopharmaceutical, with applications across oncology, cardiology, and neurology. A case study from a comprehensive cancer center illustrates the value of PET imaging: FDG-PET changed management in 30-40% of patients with lymphoma and lung cancer, identifying unsuspected metastases that altered staging and treatment planning.
Therapeutic Nuclear Medicine includes radiopharmaceuticals that deliver targeted radiation to cancer cells. The most prominent recent success is Lu-177 PSMA-617 for metastatic castration-resistant prostate cancer, which demonstrated a 38% reduction in risk of death in a landmark phase III trial. Other therapeutic agents include I-131 for thyroid cancer, Y-90 microspheres for liver cancer, and emerging agents for neuroendocrine tumors and other malignancies.
Application Landscape: Oncology, Cardiology, Thyroid, and Beyond
The oncology application segment represents the largest and fastest-growing market for nuclear medicine, encompassing both diagnostic imaging for cancer staging and response assessment, and radioligand therapy for advanced malignancies. The theranostic paradigm—using a diagnostic radiopharmaceutical to identify patients with target expression followed by therapeutic radiopharmaceutical targeting the same receptor—has become a model for precision oncology. A case study from a prostate cancer patient illustrates this approach: after progressing on multiple lines of therapy, the patient underwent Ga-68 PSMA PET imaging, which demonstrated high PSMA expression in metastatic sites, qualifying him for Lu-177 PSMA therapy, resulting in durable disease control and quality of life improvement.
The cardiology segment encompasses myocardial perfusion imaging for coronary artery disease, a well-established application with millions of procedures performed annually worldwide. Technetium-99m-labeled agents remain the workhorse for cardiac nuclear medicine, with SPECT imaging providing prognostic information that guides revascularization decisions.
The thyroid segment includes diagnostic and therapeutic applications for benign and malignant thyroid disease. I-131 therapy for hyperthyroidism and differentiated thyroid cancer represents one of the longest-standing and most successful nuclear medicine therapies.
Competitive Landscape: Global Radiopharmaceutical Leaders
The nuclear medicine market is characterized by a concentrated group of global leaders with specialized expertise in radiopharmaceutical production, distribution, and regulatory compliance.
Novartis, through its acquisition of Advanced Accelerator Applications, has established a leadership position in therapeutic radiopharmaceuticals, including Lu-177 PSMA-617 and the somatostatin analog for neuroendocrine tumors. GE Healthcare, Siemens, and Bracco Imaging maintain strong positions in PET and SPECT imaging equipment and radiopharmaceuticals.
Cardinal Health, Jubilant Pharma, Curium Pharma, and Lantheus represent the global radiopharmaceutical manufacturing and distribution leaders, with extensive networks for producing and delivering short-lived isotopes. Bayer, Eli Lilly, and Aurobindo Pharma maintain presence in specific radiopharmaceutical categories.
China Isotope & Radiation and Yantai Dongcheng serve the growing Chinese market.
Exclusive Industry Insight: The Supply Chain Imperative
The defining challenge—and opportunity—in the nuclear medicine market is the supply chain complexity inherent in radiopharmaceuticals. Most diagnostic and therapeutic isotopes have short half-lives, requiring production facilities located within distribution range of end users. Technetium-99m, derived from molybdenum-99 generators, has a 6-hour half-life; fluorine-18 has a 110-minute half-life; lutetium-177 has a 6.7-day half-life. This reality creates significant barriers to entry and competitive advantages for established manufacturers with proven supply chain capabilities.
For strategic decision-makers, the nuclear medicine market presents a compelling opportunity characterized by strong growth driven by theranostic oncology applications, expanding reimbursement, and the essential role of nuclear medicine in precision diagnosis and therapy. The projected expansion from US$ 6.88 billion to US$ 11.09 billion by 2031 reflects a market where radiopharmaceutical expertise, supply chain capability, and clinical evidence development will define competitive success.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
